63 results about "Motor dysfunction" patented technology

The invention discloses application of an NR1D1 protein phosphorylation site in preparation of cerebral hemorrhage treatment drugs, and belongs to the technical field of molecular biology. According to the invention, the specific phosphorylation site and phosphorylation modification level of the NR1D1 protein are determined for the first time, and the NR1D1 protein can be used as a key marker for evaluating the secondary nerve injury degree of the hemorrhagic cerebral apoplexy and developing treatment and / or alleviation of the hemorrhagic cerebral apoplexy; a specific antigen peptide and an antibody for accurately detecting the NR1D1 protein phosphorylation site are further constructed, and an efficient tool is provided for molecular evaluation of hemorrhagic stroke secondary nerve injury; meanwhile, polypeptide molecules capable of inhibiting NR1D1 protein phosphorylation are researched and developed, through the dual effects of specifically blocking the phosphorylation process and reducing protein degradation, necrosis of brain tissues around hematoma after hemorrhagic cerebral apoplexy is relieved, secondary dyskinesia is improved, and the effect of inhibiting NR1D1 protein phosphorylation is achieved. And a brand new scheme is provided for molecular evaluation and targeted intervention of hemorrhagic stroke secondary nerve injury.

The invention relates to hydroxylated polyamide-amine dendrimer integrated drug-loaded nanogel as well as a preparation method and application thereof. The drug-loaded nanogel comprises third-generation polyamide-amine dendrimer integrated nanogel modified by double bonds and high-density hydroxyl groups, MnO2 nanoparticles and quercetin, wherein the nanogel is loaded with MnO2 nanoparticles in situ, and quercetin is physically wrapped in the nanogel. The drug-loaded nanogel disclosed by the invention can enhance a blood-brain barrier penetrating effect, regulate microglial cells and neurons in a double-target manner and remodel a brain inflammation microenvironment, so that neuroinflammation and dyskinesia of a Parkinson's disease model mouse are relieved, and the curative effect of the Parkinson's disease is improved. The compound has good development prospect and application value in treatment of Parkinson's disease or other neurodegenerative diseases.

The application relates to the technical field of new uses of medicines, and particularly discloses application of an N-phenylpiperazine derivative in preparation of a medicine for treating Parkinson's disease, wherein the N-phenylpiperazine derivative is HS. + The N-phenylpiperazine derivative HS provided by the application can significantly improve the survival rate of SH-SY5Y cells induced by MPP + , shows a dose-dependent neuroprotective effect, can effectively improve the motor dysfunction of a model animal, increase the open field movement distance, prolong the time of staying on a rotating rod, and provides a new selection for developing an anti-Parkinson's disease treatment medicine with a neuroprotective effect.

This invention belongs to the technical field of rehabilitation robots, specifically relating to a continuous phase control method for a lower limb rehabilitation exoskeleton that adapts to user gait. It employs a multi-task learning model, simultaneously outputting user identity probability and movement pattern probability to generate a probability map representing the similarity between the current gait and a certain movement pattern of a sample user in a sample database. A gait phase variable parameter prediction model is used to predict gait phase variable parameters, employing angular velocity data from the initial stage of the current gait cycle and the matched movement pattern to predict the gait phase variable parameters for the current cycle. Finally, a pre-constructed relational constraint model corresponding to the matched sample user and their movement pattern is used to obtain the desired joint angles from the real-time gait phase, and the exoskeleton is tracked and controlled via a PD controller. This invention can adaptively adjust the exoskeleton's motion assistance mode according to the user's gait characteristics, and is suitable for rehabilitation training of patients with lower limb motor dysfunction.

The present invention relates to the technical field of neural stimulation, and specifically relates to a non-invasive spinal cord stimulator for upper limb motor function recovery, comprising a cervical spinal cord pulse control unit, an electrode connection unit, a motion monitoring unit, a wireless communication unit, a speech unit, a paradigm decision unit, an electrode array unit, and an artificial intelligence unit. In the present invention, the non-invasive spinal cord stimulator acts on a specific cervical spinal cord segment by means of non-invasive cervical spinal cord stimulation technology, inducing the reconstruction of a spinal cord neural network, strengthening synaptic connection, treating upper limb motor dysfunction of paralyzed individuals, and achieving upper limb motor function recovery.

The invention belongs to the technical field of biomedical signal processing, and particularly relates to a surface electromyogram signal-based upper limb movement function evaluation method for a stroke patient. The method comprises the steps of subject selection, electrode arrangement and signal acquisition, experimental normal form design, surface electromyographic signal preprocessing, macroscopic electromyographic feature extraction and microscopic electromyographic feature extraction. The method comprises the following steps: collecting surface electromyogram signals under a plurality of specific gestures, extracting eight macroscopic features and two microcosmic features, and constructing a model for Brunnstrom stage classification and upper limb Fugl-Meyer scoring prediction by using a K nearest neighbor algorithm; through systematic comparison of an affected side, an uninjured side and a healthy control group of a stroke patient, accurate quantification of the degree of stroke dyskinesia is realized, and objectivity, fineness and clinical practicability of evaluation are improved; manual evaluation deviation and time consumption can be greatly reduced, and an objective and real-time evaluation basis is provided for formulating a personalized rehabilitation scheme.

The application discloses a multi-degree-of-freedom bionic foot rehabilitation robot device, which comprises an outer frame, a four-section bionic foot sole plate and a parallel driving mechanism. The four-section bionic foot sole plate is connected through a rotating shaft hinge and a slider and slide rod structure, and simulates the biomechanical movement of the rear foot area, the middle foot area, the front foot area and the toe bone area of a human foot. The parallel driving mechanism adjusts the posture of each foot sole plate section, realizes the multi-degree-of-freedom movement and deformation compensation of the ankle joint and the foot, and is wearable on the foot and suitable for the rehabilitation training of patients with lower limb motor dysfunction.

Methods and compositions for manipulating metabolism in astrocytes to improve astrocytic and neuronal function, as well as individual pathology hallmarks and symptoms during the development of neurodegeneration by increasing PPARα expression and activity specifically in astrocytes within the central nervous system to treat a variety of neurodegenerative conditions including but not limited to conditions involving neuronal lipid dysregulation, oxidative damage, accumulation of β-amyloid or other protein aggregates, dementia, and motor dysfunction. Also provided are methods of treating peripheral metabolic dysfunction associated with neurodegenerative conditions.

The invention belongs to the related technical field of rehabilitation robots, and particularly relates to a user gait self-adaptive lower limb rehabilitation exoskeleton continuous phase control method, which adopts a multi-task learning model, outputs a user identity probability and a motion mode probability at the same time, generates a probability graph, and provides a user gait self-adaptive lower limb rehabilitation exoskeleton continuous phase control method. And representing the similarity between the current gait and a certain movement mode of a certain sample user in the sample library. And a gait phase variable parameter prediction model is adopted to predict a gait phase variable parameter, and the gait phase variable parameter of the current period is predicted by using the angular velocity data of the initial stage of the current gait period and the matched motion mode. And finally, obtaining an expected joint angle through a real-time gait phase by adopting a pre-constructed relation constraint model corresponding to the sample user obtained by matching and the motion mode of the sample user, and realizing tracking control of the exoskeleton through a PD controller. The motion assisting mode of the exoskeleton can be adjusted in a self-adaptive mode according to the gait characteristics of the user, and the method is suitable for rehabilitation training of patients with lower limb motion dysfunction.

The invention provides a traditional Chinese medicine composition for treating Parkinson's depression and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-10 parts of radix acanthopanacis semticosi and 1-10 parts of bulbus lilii. The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: taking the acanthopanax and the lily, adding water to soak, heating, refluxing and extracting, and combining filtrate to obtain the traditional Chinese medicine composition. Animal experiments find that the acanthopanax-lily traditional Chinese medicine composition has a good treatment effect on Parkinson depression for the first time, and can remarkably improve dyskinesia and depression symptoms, regulate neurotransmitter disorder, relieve damage to nigra and hippocampal neurons and reduce the level of inflammatory factors in serum. After being taken for a long time, the traditional Chinese medicine composition disclosed by the invention can improve depression and life quality, slow down the progress of Parkinson disease and reduce the use of Parkinson drugs.

The application discloses a gait evaluation method and device, electronic equipment and storage medium, and relates to the technical field of gait analysis. In the application, gait data of a person with motor dysfunction in adjacent multiple walking cycles is obtained; the gait data comprises a gait phase parameter set and a posture angle parameter set of the person with motor dysfunction; from the gait phase parameter set and the posture angle parameter set included in the gait data, a gait phase parameter subset and a posture angle parameter subset corresponding to each of multiple gait evaluation dimensions are determined; based on the gait phase parameter subset and the posture angle parameter subset corresponding to each of the multiple gait evaluation dimensions, gait evaluation of the person with motor dysfunction is performed in the multiple gait evaluation dimensions to obtain multiple gait evaluation values; and based on the multiple gait evaluation values and gait evaluation weight values corresponding to the multiple gait evaluation values respectively, a comprehensive gait evaluation value of the person with motor dysfunction is determined. In this way, the gait data of the person with motor dysfunction is comprehensively quantified, and the accuracy of gait evaluation is improved.

The invention provides a plant-derived active polypeptide and application thereof in prevention or treatment of Parkinson's syndrome, and belongs to the technical field of polypeptide bioengineering. The amino acid sequence of the active polypeptide is MKGASSIMYALG, and the active polypeptide is prepared from Fuding white tea raw materials through a directional two-step enzymolysis process. According to the polypeptide, the damage of 6-OHDA induced BZ555 nematode dopaminergic neurons can be remarkably reduced, and the dyskinesia of Parkinson's syndrome model animals can be remarkably improved; meanwhile, the expression level of proinflammatory factors such as IL-1beta and IL-18 in serum of a model mouse can be lowered, the content of dopamine in a nigra area of brain tissue of the model mouse can be increased, and the activity of monoamine oxidase B can be reduced. The results show that the Fuding white tea-derived active polypeptide has exact prevention and treatment effects on Parkinson's syndrome, and has important development value and wide application prospects in the field of medicines.

The present invention provides a method and device for treating motor dysfunction after spinal cord injury by targeting the lateral hypothalamus (LHA). Specifically, in the present invention, by performing electrical stimulation on glutamatergic neurons in the dorsal part of the caudal LHA, the LHA-PnO-spinal cord circuit is activated to modulate limb motor function in patients with spinal cord injury. The method of the present invention has small side effects and can serve as a potential approach for restoring voluntary motor function in patients with spinal cord injury.

The invention discloses a preparation method and application of ganoderma lucidum outer vesicles without sporocarp waste sources. The ganoderma lucidum external vesicles are used for preparing medicines for treating ischemic cerebral apoplexy sequelae, and can improve core symptoms such as dyskinesia (including limb paralysis, imbalance and gait abnormity), cognitive decline and the like after apoplexy. The spore-free sporocarp waste sourced ganoderma lucidum outer vesicles are prepared from spore-free sporocarp waste which is completely released by spores after a ganoderma lucidum powder spraying period through raw material pretreatment, differential centrifugation, tangential flow concentration and filter membrane filtration. According to the preparation method, the waste is used as a raw material to prepare the high-value medical outer vesicle, green circulation of agricultural waste-high-added-value medical raw materials is achieved, the ganoderma lucidum outer vesicle can effectively penetrate through the blood-brain barrier, brain-targeted delivery is achieved, and the problems that traditional ganoderma lucidum active ingredients are low in blood-brain barrier penetration rate and poor in blood-brain barrier penetration rate are solved. The effective treatment concentration in the brain tissue is difficult to achieve, and the traditional drug delivery bottleneck is broken through.

A drilling system may determine a change in motor torque and / or a pressure drop of a downhole motor based on a flow of a drilling fluid through the downhole motor. The drilling system may determine a change in bit torque of a bit with respect to a change in a weight on bit of the bit. Based at least in part on the change in motor pressure and the change in bit torque of the bit with respect to the change in the weight on bit of the bit, the drilling system may adjust a flow rate of the drilling fluid through the downhole motor to reduce a frequency of motor stalls of the downhole motor.

The present invention relates to a primate model of central motor function impairment. More specifically, the present invention provides: a primate model of central motor function impairment, in which the use of the hand is lost due to damage to a brain region associated with manual dexterity, from immediately after the damage through the acute and chronic periods, while functions of other regions are preserved; and a method for producing the model.

This utility model relates to a leg exercise device for neurological rehabilitation, belonging to the technical field of leg exercise devices. It includes a seat assembly and two symmetrically arranged leg training mechanisms. Each training mechanism includes a control component and a training component. The training component includes a hip joint mechanism hinged to the seat assembly, a large arm guard hinged to the hip joint mechanism, and a forearm guard hinged to the distal end of the large arm guard. Servo direct drive mechanisms are provided at both the hip and knee joint hinges. A magnetorheological fluid rotary damper is coaxially arranged at the knee joint hinge. A travel limit sensor and a torque sensor for muscle tension detection are provided at the hinge. The servo direct drive mechanism, the magnetorheological fluid rotary damper, and the torque sensor are all electrically connected to the control component. It features a built-in passive, assisted active, and resistance-enhanced three-level training mode and bilateral independent operation. This utility model, through its three-level training mode, can cover the training of patients with lower limb motor dysfunction in neurology, lowering the rehabilitation threshold for patients.

The invention relates to a compound for targeted degradation of alpha-synuclein or a pharmaceutically acceptable salt thereof as well as a preparation method and application of the compound. The structural formula of the compound for targeted degradation of alpha-synuclein is shown as a general formula (I), the compound can degrade alpha-synuclein protein with a low dosage in vitro, levodopa is selected as a positive drug in an in-vivo experiment, it is proved that the compound can relieve dyskinesia caused by the Parkinson's disease, and the compound can be applied to drugs for relieving symptoms of the Parkinson's disease.

The invention belongs to the technical field of medicines, and finds an application of a compound esculetin as shown in a formula I and a precursor thereof in preparation of a medicine for promoting repair of dyskinesia and neurological impairment in a subacute stage-recovery stage after cerebral arterial thrombosis. It is found that the compound esculetin can significantly reduce the area and volume of infarction after cerebral arterial thrombosis and promote repair of dyskinesia and neurological impairment after cerebral arterial thrombosis, which is shown in improvement of sensory movement and posture asymmetry after cerebral arterial thrombosis and enhancement of forelimb movement function and limb coordination. The esculetin can be used for remarkably reducing neuron injury caused by cerebral ischemia. The compound can be used for preparing medicines for promoting the repair of dyskinesia and neurological function damage in the subacute stage-recovery stage after cerebral apoplexy.

The application discloses a kind of across patient phase identification and gait assessment method, belong to rehabilitation medical technical field.The method includes: the friction electricity signal generated when the lower limb of the patient to be measured is collected, obtains multimodal data;Multimodal data is used as input information, and gait assessment result and gait phase identification result are obtained by multitask model;Multitask model includes representation learning base network, unsupervised domain adaptation layer, mixed multitask layer;Representation learning base network extracts high-level features from multimodal data;Unsupervised domain adaptation layer obtains features by domain adaptation layer with weight parameter, and the features are mapped to a higher-dimensional latent feature space to obtain shared features;Mixed multitask layer inputs shared features into the independent subnetwork of multitask, and the gait assessment result and gait phase identification result of the patient to be measured are correspondingly output.The lower limb motor dysfunction patient is better to carry out rehabilitation training.

The invention discloses a novel monomer MJP6 in black garlic, a preparation method of the novel monomer MJP6 and application of the novel monomer MJP6 in preparation of a medicine for treating cerebral hemorrhage. The application of the compound MJP6 in preparing the medicine for treating cerebral hemorrhage has at least one of the following characteristics: the MJP6 has an intracerebral nerve protection effect; the MJP6 has a repairing effect on brain ultrastructure damage; the MJP6 has the effects of inhibiting intracerebral inflammation and infiltration of microglial cells and neutrophil; mJP6 promotes intracerebral hematoma absorption and blood flow recovery; the MJP6 has the effect of relieving dyskinesia.

The application discloses application of bupropion hydrochloride tablets (75mg) in preparation of a medicine for treating stroke, and belongs to the technical field of new purposes of medicines. The core verifies the efficacy and safety of the medicine of the specification through systematic animal tests, aims at the problems of post-stroke neural function defect, motor dysfunction and insufficient neural plasticity, adopts a line plug method to prepare a rat focal cerebral ischemia (MCAO) model, sets multiple control tests, and explores the dosing effect of an equivalent dose of the bupropion hydrochloride tablets (75mg). The test results show that the medicine can significantly reduce the neural function defect score of the model animals, improve the motor coordination ability and the limb usage rate, increase the content of brain-derived neurotrophic factor (BDNF) in the brain, promote the repair of neural plasticity, and is safer than a high-dose scheme and has no obvious adverse reactions. Through complete animal test data, the application proves the effectiveness and safety of the bupropion hydrochloride tablets (75mg) in treating stroke, provides solid test basis for clinical conversion and application of the bupropion hydrochloride tablets (75mg), and has important medical application value.

The application discloses strains for preventing and treating Parkinson's disease and compositions, applications and products thereof, and relates to the technical field of microorganisms.The application provides three strains of human milk origin, namely Lactobacillus helveticus LV-20, Lactobacillus plantarum LPP8 and Lactobacillus fermentum PL-15.The application also provides a composition capable of preventing and treating Parkinson's disease.The three strains can preferably prevent and treat Parkinson's disease.The composition can significantly improve motor dysfunction (such as static tremor, muscle rigidity, bradykinesia, posture balance and the like), reduce neuron damage, significantly reduce alpha-syn deposition, reverse sensory function degradation and cognitive impairment, relieve sleep disorders, inhibit neural inflammation and oxidative stress, reduce and repair intestinal barrier damage, relieve gastrointestinal dysfunction, improve constipation and regulate intestinal flora composition, and has a wide application prospect as a probiotic or synbiotic product for treating and preventing Parkinson's disease.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN3 RNA in a cell or animal, and in certain embodiments reducing the amount of ATXN3 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include motor dysfunction, aggregation formation, and neuron death. Such neurodegenerative diseases include spinocerebellar ataxia type 3 (SCA3).

The invention provides a dyskinesia analysis method, device and equipment for fracture postoperative rehabilitation, a storage medium and a program product, and relates to the technical field of artificial intelligence, the method comprises the following steps: carrying out space-time decomposition on a joint angle matrix to obtain a first space pattern matrix and a first time pattern matrix, and carrying out space-time decomposition on an electromyographic signal matrix to obtain a second space pattern matrix and a second time pattern matrix; obtaining a second spatial pattern matrix and a second time pattern matrix; clustering the first spatial pattern matrix and the first time pattern matrix based on the optimal cooperative pattern number to generate a joint cooperative feature matrix, and clustering the second spatial pattern matrix and the second time pattern matrix to generate a muscle cooperative feature matrix; and inputting the joint collaboration feature matrix and the muscle collaboration feature matrix into a pre-trained dyskinesia evaluation model to obtain a lesion score. By means of the mode, the accuracy of model prediction can be improved, and accurate quantitative analysis on the dyskinesia degree of the user is achieved.

Provided is a closed-loop neuromodulation system involving coordinated intervention of the brain, the spinal cord, and the lumbosacral region, which comprises a deep brain stimulation unit (401), a deep brain field potential sensing unit (402), a spinal cord stimulation unit (501), an evoked potential sensing unit (502), a control decision-making unit (10), a deep brain electrode (403), a spinal cord electrode (503), a lumbosacral electrode (602), a docking lead (601), a radio frequency transmission unit (20), and a wireless charging and power management unit (30). By constructing an application strategy for coordinated regulation of the brain, the spinal cord, and the lumbosacral region, only one neurostimulator needs to be implanted. It can be used alone for brain diseases or spinal cord-related diseases, and can also be used for coordinated stimulation for motor function reconstruction and recovery in paralyzed patients and patients with motor dysfunction, as well as for the treatment of urinary system complications. The whole system is modular in application, can be selectively used according to disease conditions, and has a wider application range.

The invention relates to a neural stem cell-parathymosin composite cell preparation and application thereof in treatment of nerve injury diseases. According to the invention, it is found for the first time that neural stem cells overexpressing parathymosin (PTMS) can effectively promote neuron neogenesis and axon growth in in-vitro and in-vivo experiments; animal experiment results show that the traditional Chinese medicine composition can also be used as a treatment means for promoting nerve regeneration to resist dyskinesia related to nerve injury diseases.

The application discloses application of brain-type creatine kinase in preparation of a medicine for preventing or treating Parkinson's disease, belongs to the technical field of genetic engineering, and provides the application of brain-type creatine kinase in preparation of the medicine for preventing or treating Parkinson's disease, wherein the amino acid sequence of the brain-type creatine kinase is shown as SEQ ID NO. 6. The application of brain-type creatine kinase as a treatment target in screening of the medicine for preventing or treating Parkinson's disease. The application firstly finds that in a Parkinson's disease mouse model, reducing expression of brain-type creatine kinase (CKB) increases loss and death of dopaminergic neurons in the substantia nigra pars compacta of the Parkinson's disease mouse, and significantly aggravates motor dysfunction of the Parkinson's disease mouse; overexpression of CKB obviously reduces damage of Parkinson's disease neurons. The CKB protein is a new target for preventing and treating Parkinson's disease, can be used for screening and finding the medicine for preventing and treating Parkinson's disease, can inhibit death of dopaminergic neurons by improving CKB expression, and realizes the effect of preventing and treating Parkinson's disease.

The invention discloses human-derived lactobacillus johnsonii HA1108 and application thereof in preparation of biological agents and / or medicines for treating or relieving Parkinson's disease, and belongs to the technical field of biological medicines. The invention provides a strain of lactobacillus johnsonii, which is classified and named as Lactobacillus johnsonii, and the preservation number of the lactobacillus johnsonii is CGMCC (China General Microbiological Culture Collection Center) No.35865. Based on'flora-intestine-brain axis', the lactobacillus johnsonii HA1108 can improve dyskinesia in Parkinson's disease, relieve deletion of dopaminergic neurons of nigra in the brain, increase protein expression of tyrosine hydroxylase at the nigra part in the brain, and improve the immunity of the Parkinson's disease. The microbial inoculum prepared from the lactobacillus johnsonii HA1108 does not affect the body weight after being eaten for a long time, and a new choice is provided for patients with Parkinson's disease. The screened lactobacillus johnsonii HA1108 has important significance in preparation of biological agents or medicines for treating or relieving Parkinson's disease, improving dyskinesia and improving tyrosine hydroxylase expression, has safety and application value, and is wide in market prospect.